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Lymphocyte Subsets as Surrogate Markers in Antiretroviral Therapy 
Summary: Efficacy of antiretroviral treatment is evalu-
ated usually according to reduction of serious events 
(e.g. opportunistic infections while on therapy) and im-
provement of survival time. In stages of asymptomatic 
disease treatment trials have to cover very long time pe-
riods to fulfil these requirements. In asymptomatic sta-
ges, when viremia is commonly absent, monitoring the 
host's immune response is an indirect means of mea-
suring antiviral efficacy. CD4 + lymphocyte counts are 
generally accepted as surrogate in all major trials. The 
subsets of the CD8 + compartment reflect early and 
late activation and cytotoxic immune response. 
CD38 + , CD57, CD8 + HLA/DR+ subsets reflect the 
host's vigorous cellular immune response even in early 
stages. These subsets are candidate surrogate markers 
in early and late stages of HIV infection. On the 
other hand, CD3 + CD4- CD8-, CD19/20 (B lympho-
cytes) and CD16+ (natural killer cells) do not exhibit 
any properties of candidate surrogate markers. Estab-
lished and experimental cellular surrogate markers are 
discussed including own data and a review of the litera-
ture. 
Zusammenfassung: Lymphozytensubpopulationen als 
Surrogatmarker bei antiretroviraler Therapie. Die Beur-
teilung der Effektivität einer antiretroviralen Therapie 
geschieht überwiegend anhand der Krankheitsprogre-
dienz und der Überlebenszeit. Es besteht Interesse an 
Surrogatmarkern, die eine Aussage zu Wirksamkeit der 
Therapie ermöglichen, bevor es zu einer Progredienz 
kommt und solange ein asymptomatisches Stadium vor-
liegt. Gerade während asymptomatischer Stadien bie-
ten sich Parameter, welche die Immunantwort auf die 
HIV-Infektion widerspiegeln, hierfür an, da eine Vir-
ämie meist noch nicht vorliegt. Die einzigen derzeit 
etablierten Surrogatmarker unter den Lymphozyten-
Subsets sind CD4 + und CD8 + Lymphozyten. Anhand 
eigener Ergebnisse und Diskussion der Literatur wird 
auf die Möglichkeit neuer Subset-Untersuchungen ein-
gegangen: Die Aufgliederung der CD8 + Zellen mit 
Markern für Aktivierung und Zytotoxizität (HLA/DR, 
CD38, CD57) ermöglicht eine stadienabhängige Beur-
teilung der Beeinflussung von zytotoxischer Immunant-
wort als Auswirkung der HIV-Immunpathogenese. An-
dere Subsets, wie beispielsweise B-Lymphozyten, 
CD3 -f 4-8-Lymphozyten und Killerzellen eignen sich 
theoretisch weniger gut als Surrogatmarker. 
Introduction 
When AIDS was first discovered clinical diagnoses of in-
fections and neoplasms due to immunodeficiency were the 
Figure 1: Model of viremia and host immune response in the 
course of HIV infection. The asymptomatic period is character-
ized by efficaceous virus containment due to humoral and cell 
mediated immunity. In this stage monitoring of the host's im-
mune response serves as candidate surrogate for antiviral effi-
cacy (rather than parameters of viremia). 
CMI = cell mediated immune response; C T L = cytotoxic lymphocyte; 
A R C = A I D S related complex. 
clue to diagnosis {Pneumocystis carinii pneumonia, candi-
diasis, Kaposi's sarcoma). A profound change in the rela-
tion of suppressor and helper Τ lymphocytes resulting in 
an inversion of the ratio of CD4 + and CD8 + cells was 
the immunological "surrogate" for the syndrome when no 
clinical signs were apparent in patients at risk [1]. 
In addition to this quantitative disturbance, a decreased 
lymphocyte proliferation was observed upon stimulation 
with mitogens and antigens in vitro. 
After almost one decade the natural history is known quite 
well in many facets. The corresponding immunopathogen-
esis is characterized in many aspects, including the se­
quential changes of cellular immunity in the course of HIV 
infection. Efficacy of antiviral treatment is evaluated usu­
ally according to reduction of serious events (e.g. opportu­
nistic infections while on therapy) and prolongation of sur­
vival. In stages of asymptomatic disease, treatment trials 
have to cover very long time periods to fulfil these require­
ments. Reliable surrogates indicating antiretroviral effica­
cy therefore could contribute to a better feasibility of clini­
cal trials. Theoretically, virological and immunological pa­
rameters are not equally useful as surrogate markers in 
every stage, as demonstrated in F igure 1: antigen detec­
tion is more likely in symptomatic disease as compared 
with asymptomatic stages. 
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Table 1: Quantitative changes of lymphocyte subsets in the * PERIPHERAL BLOOD 
course of HIV infection. Μ 
Lymphocyte subset 60 
CD4 + * Depletion 50 
CD4 + CDw29 + + Earlier depletion 
CD3 + CD4 - CD8 - - Minor expansion 40 
CD8 + H L A / D R + + Early expansion 
CD8 + CD38 + + Late expansion 30 
CD8 + CD57 + + Expansion 
CD3 + CD8 + CD25 + ? 20 
H L A / D R + -
C D 16+ (NK) - No or only slight quantitative 10 
change 
C D 19; CD20 - No or only slight quantitative 00 
change 
Generally accepted (*) and candidate ( + ) surrogate markers; ( - ) = no 
properties of a surrogate. 
In earlier stages of HIV infection the monitoring of the 
host's immune response (humoral and cellular) is possibly 
a suitable way of monitoring the effects of viral burden 
and immunopathogenicity of HIV disease. The determina­
tion of quantitative and qualitative changes of cellular im­
munity as a possible surrogate marker of efficacy in anti­
retroviral therapy will be discussed in this paper. 
Quantitative Kinetics of Lymphocyte Subsets in the 
Course of HIV Infection 
An overview on increase and decrease of lymphocyte sub­
sets during HIV infection is given in Tab le 1. Expansion of 
lymphocyte subsets mainly occurs in CD8 + lymphocytes 
and in the corresponding subsets of CD8 + cells and acti­
vated Τ lymphocytes. Most attention, however, is usually 
paid to the loss in percentage and absolute numbers of 
CD4 + lymphocytes. 
CD4+ Lymphocytes 
Helper lymphocytes (CD4 + ) constitute the center of cel­
lular immune responses. Even humoral responses are 
facilitated or at least enhanced by CD4-t- lymphocytes. 
The depletion of this subset of Τ lymphocytes results in a 
major immunodeficiency mainly of the cellular responses. 
Furthermore, the CD4 + cell with its CD4 molecule is the 
main target for HIV [2]. The severity of CD4 + cell deple­
tion is taken as a parameter for the severity of immunode­
ficiency and for prognosis. This is why this number has been 
introduced in one of the major classification systems, the 
Walter Reed (WR) staging classification [3]: the number 
of 400/μ1 makes up the discrimination between stage WR 2 
and WR 3. 
CD4 + lymphocyte subset results of our patients in WR 1 
are significantly lower than in controls (p<0.001; F igure 
2) , indicating an early reduction of this subset [4]. Lang 
and colleagues studied 39 seroconverters [5]. An early and 
CD8 D CD4 
* p<0.0001 
CONTROLS WR1 WR2 WR3 WR4 WR5 WR6 pr e f i n a l 
n= 30 29 33 18 16 26 40 11 
Figure 2: Proportion of CD4 + and CD8 + lymphocytes in the 
course of HIV infection according to Walter Reed (WR) stages. 
In WR 1 significant differences as compared with controls 
could be detected. 
S E M = standard error of the mean. 
sustained reduction could be observed. This result was al­
so confirmed by data published from the Multicenter 
AIDS Cohort Study. Within 12 to 18 months after sero­
conversion the reduction of CD4 4- cells reaches approxi­
mately 60% of the baseline count prior to seroconversion 
[6]. The count then stays relatively stable during the subse­
quent asymptomatic years (Figure 1) [7]. The period be­
fore the onset of ARC and AIDS is characterized by a rap­
id CD4+ cell depletion [8]. 
The application of the CD4 + count as a surrogate marker 
for efficacy of antiretroviral treatment mainly depends on 
the stage studied. In the past most clinical trials were 
supplemented by determination of this parameter before 
and during therapy. Generally an expansion of the CD4 + 
subset is taken as a sign of efficacy [8, 9]. 
Zidovudine therapy, for example, results in a minor in­
crease during the first months of treatment. The mean 
CD4+ count rose from 356 ±201/μ1 to 435 ±288/μ1 in 
long-term treatment of our patients (Figure 3) . 
The use of CD4 + counts as surrogate markers is an indi­
rect method for rating the antiviral efficacy: if the CD4 + 
cell depletion is caused by increased viral burden, an in­
version of this process should be taken as a sign of antiret­
roviral effects. 
However, early treatment in stages of stable CD4 + count 
might cause difficulties in evaluation (Figure 4): in a peri­
od characterized by stable CD4 + counts an expansion 
seems less probable: in the trial of zidovudine in asympto­
matic patients with CD4 + lymphocytes more than 200/μ1 
an increase of helper cells could be shown statistically only 
in qualitative nonparametric testing but not in a quantita­
tive comparison [9]. 
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Figure 3: Expansion of C D 4 + lymphocytes in patients on zido­
vudine treatment. 
η = 10; S E M = standard error of the mean. 
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Figure 4: Model of depletion of CD4+ lymphocytes in the 
course of HIV infection [4-7, 10]. The loss of CD4 + CDw29 
(memory) cells accounts for a major part of the early CD4 4 de­
pletion [10]. 
Evidence is given in recent studies, that the 
CD4 + CDw29+ subset within the CD44 lymphocytes is 
decreased at first (Figure 4) [10]. Therefore, this particu­
lar subset is a candidate surrogate marker in early treat­
ment trials. Detailed knowledge about the kinetics of 
CD4 + CDw29+ lymphocytes during antiretroviral treat­
ment could be the subject of any further trial in asympto­
matic patients. Functionally the CD4 + CDw29+ cells 
show strong helper function for the induction of IgG re­
sponse to recall antigens (memory function). 
CDS 4 Lymphocytes 
The application of two and three color flow cytometry de­
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Figure 5: Model of the expansion of CD8+ lymphocytes in the 
course of HIV infection [4-6 ,14] . CD8 + subsets bearing mark­
ers of activation and cytotoxicity expand in early (CD57 4 , HLA/ 
DR + ), intermediate (CD5 + ) and late (CD38 + ) stages of HIV 
infection [4, 14]. 
tional monoclonal antibodies directed against surface mol­
ecules typical for a state of activation of cytotoxicity are 
Leul7 (CD38), Leu7 (CD57), Leu8, and HLA/DR. 
CD38 occurs on activated Τ lymphocytes, thymocytes, nat­
ural killer (NK) cells and on some Β lymphocytes. CD57 is 
a marker for cytotoxic Τ lymphocytes (in combination with 
CD8 and/or CD3). On the surface of Τ lymphocytes HLA/ 
DR is a marker of cell activation [11]. 
Initially the inversion of the CD4/CD8 ratio was regarded 
as the hallmark of the acquired immunodeficiency and the 
major explanation was seen in the CD44 depletion. How­
ever, as early as 1983 to 1985 some reports pointed out 
that not only the relative but also the absolute CD8 + 
counts were expanded [12, 13]. 
CD8 4 counts of 1500 to 2500/μ1 are commonly found in 
HIV-infected patients. The (falsely) low determination of 
CD8 4- cells after lymphocyte separation on a Ficoll gra­
dient is corrected by a wide use of the lysed whole blood 
preparation (in which the obvious loss of CD8 4 cells does 
not occur). 
Up to 70% of circulating lymphocytes are CD8 4- cells in 
some patients. The expansion of the CD8 + compartment 
is an event of early HIV infection. Again, a significant in­
crease is found as early as WR 1 [4]. Monitoring the lym­
phocyte subsets in seroconverters reveals an increase al­
ready at seroconversion [5, 6] (Figure 5) . 
A further development of the CD8 4- compartment shows 
a stage dependent sequential pattern [14-16,4) (Figure 5) . 
Thus the early expansion of CD8 4 cells is caused by an in­
crease of CD84Leu8- lymphocytes, CD8 4 HLA/DR 4 
and CD8 4 CD58 4 (Figure 5) . The ratio of CD8 + Leu8 4-
to CD8 4 Leu8- lymphocytes decreases. The CD8 4 Leu8-
subset parallels the lymphocyte depletion and does not 
participate in the CD84 expansion [14]. CD84CD384 
lymphocytes increase with progression towards full-blown 
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AIDS. In the late stages ARC and AIDS most of the 
CD8 + cells also carry the CD38 molecule (Figure 5) . 
Two colour flow cytometry using CD57 shows that 
CD8 + CD57 + as well as CD8 + CD57- cells expand in 
early HIV infection [15,16,4]. A similar expansion is seen 
in rejection of renal allografts [17]. Functionally 
CD8 + CD38 + and CD8 + CD57 + lymphocytes are in­
volved in cytotoxicity against HIV-infected cellular targets 
[15]. In addition, antibody dependent cytotoxicity 
(ADCC) is triggered by antibodies to HIV antigens and 
may be conveyed by this cell type. Lymphocyte autoanti­
bodies against CD4 + lymphocytes [18] contribute to cytol-
ysis and helper cell depletion (even of noninfected lym­
phocytes). 
In ten of our ARC patients treated with zidovudine 
(1000 mg/d) the average proportion of HLA/DR + Τ lym­
phocytes dropped from 43.9% to 38.4% of peripheral lym­
phocytes after three months of therapy (p = 0.07, Mann-
Whitney Test). However, this result has to be compared 
with a control group. While according to the natural histo­
ry in ARC a steady or even increasing count of HLA/ 
DR + Τ lymphocytes is to be expected, this result shows a 
decrease, most probably as an effect of treatment (Figure 
6). 
A small subset within the CD8 + compartment character­
ized as CD8 + CD3 + CD25 + HLA/DR + has been shown 
to exert a suppressive action on HIV replication in vitro 
[19]. Less than 10% of all CD8+ cells are of this pheno-
type. Walker and colleagues presented data on a soluble 
factor in the supernatant of cloned CD8 + CD3 + CD25 + -
HLA/DR + cells acting in a suppressive fashion. 
Knowledge presented here on the kinetics and subsets of 
CD8 + lymphocytes refers to the natural history of HIV 
infection. Data on CD8 + counts as surrogate marker for 
antiretroviral therapy are exceptional while the ratio of 
CD4+ and CD8+ cells has often been monitored in clini­
cal trials. The Laennec HIV Study Group reported on cy­
closporin treatment of HIV infected patients: CD8 + 
lymphocytes decreased significantly while CD4 + cells of 
patients with a baseline count of 300 to 600/μ1 showed a 
lasting increase [20]. Both subsets returned to baseline 
levels after three to six months of treatment. 
Our own data on ARC patients treated with zidovudine 
are shown in Figure 6: after one year of treatment the av­
erage CD8 + count rises. Further studies should include a 
differentiation of the CD8 + subsets: a disproportional 
decrease of CD8 + CD38 + and CD8 + CD57 + cells in 
combination with a normalizing Leu8 + /Leu8- ratio could 
indicate an effect on the immunopathogenesis (in contrast 
to a progression according to natural history). 
CD3 + CD4-CD8- Lymphocytes 
CD3 + CD4-CD8- lymphocytes (double negative Τ lym­
phocytes) expand in the course of HIV infection in pe­
ripheral blood as well as in lymph nodes [21,22]. A very 
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Figure 6: Activated Τ lymphocytes (CD3 +HLA/DR+ ) before 
and after 3 months of zidovudine therapy. 
η = 10; S E M = standard error of the mean; ρ = 0.07. 
small proportion of Τ lymphocytes usually bears this phe-
notype (<3%). In vitro CD3 + CD4-CD8- cells develop to 
either CD4 + or CD8 + lymphocytes. The expansion of 
this subset represents the increased turnover of Τ lympho­
cytes [21]. While theoretically CD3 + CD4-CD8- cells 
might serve as a surrogate marker, practical application is 
limited: the proportion of CD3 + CD4-CD8- cells is a 
computed number. The difference of all CD3 + cells and 
the sum of CD4 + and CD8 + results in the number of 
CD3 + CD4-CD8- cells [22]. Because of electronical gat­
ing in flow cytometry results are not reliably reproduced in 
single determinations. 
Other Subsets 
Lymphocyte subsets of non-T-cell origin like Β lympho­
cytes (CD19 + , CD20 + ) or natural killer (NK) cells 
(CD16 + ) do not vary quantitatively in the course of HIV 
infection. Thus, they cannot be regarded as candidate sur­
rogate markers. The proportion of another type of lym­
phocytes, the "unstained cells" (morphology like lympho­
cytes but without binding of any monoclonal antibodies 
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against lymphocyte markers) rises towards final stages. Up 
to now, there is no experience as to whether this subset is 
useful as a surrogate in corresponding stages. 
In Vitro Proliferation of Lymphocytes 
The functional disturbance of the immune response caused 
by HIV infection mainly is known as diminished prolifera­
tion upon mitogen and antigen stimulation [12]. This phe­
nomenon is not necessarily linked to T-cell or helper-cell 
depletion. Teeuwsen [23] and colleagues presented find­
ings indicating reduced proliferation three months after 
seroconversion. Clenci et al. pointed out four different 
patterns of dysfunction independent of the WR stage or 
CD4+ count [22]. 
T-cell colony formation (T-CFC) of peripheral mononu­
clear cells is reduced in patients with HIV disease. Ε. M. 
Levy and colleagues observed the restoration of T-CFC in 
the course of zidovudine treatment of three months. This 
assay seems to be a sensitive surrogate of antiretroviral ef­
ficacy [24]. 
General Considerations 
The use of lymphocyte subsets as surrogate markers is only 
possible when basic requirements are met: the method of 
lymphocyte preparation and differentiation should be re­
producible and well established. A problem of multicenter 
studies is the diversity of methods (e.g. monoclonal anti­
bodies from different clones and of different affinity) in 
participating immunological laboratories. 
Absolute and relative counts of lymphocyte subsets may 
differ in reproducibility. Any discordance in the leukocyte 
differential count contributes to a multiplicative error in 
the computed absolute number. In a clinical trial absolute 
as well as relative counts should be monitored. 
Whenever lymphocyte separation is necessary for a test 
(e.g. lymphocyte culture or stimulation) at least 20 ml of 
peripheral blood are required. The test therefore cannot 
be applied for a frequent follow-up because patients tend 
to be anemic anyway. 
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